Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth CorpfiledCriticalWyeth Corp
Priority claimed from PCT/US2000/030529external-prioritypatent/WO2001034586A2/en
Publication of MXPA02004655ApublicationCriticalpatent/MXPA02004655A/en
This invention provides compounds and methods using them to provide neuroprotection and prevent or limit processes of neurodegeneration in mammals, including Alzeimer's Disease, Huntington's Disease, Parkinson's Disease, AIDS dementia, retinal disease, diabetic peripheral neuropathy, multiple sclerosis, stroke, acute thromboembolic stroke, focal ischemia, global ischemia, transient ischemic attack, ischemia resulting from surgery, head trauma, spinal trauma, hypoxia, fetal hypoxia, and neuroprotection; the compounds having the structure (I), wherein X is -CH2- or a bond; Y is -(CH2)m- or -(CH2)-O-(CH2)-; m is 0 or 1; n is 0 or 1; R1 and R2 are independently selected from optionally substituted aryl or heteroaryl, the optical isomers and the pharmaceutically acceptable salts thereof.
MXPA02004655A1999-11-122000-11-06Branched adamantyl and noradamantyl aryl- and aralkylpiperazines with serotonin 5-ht1a.
MXPA02004655A
(en)